Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 17/20 | 0.43 |
| ▸ | PDE1C | Q14123 | 5/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | TNKS | O95271 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.37 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4510882 | 0.80 | PDE10A (0.44) | PDE9APDE1CTYK2 | |
| SCHEMBL13865980 | 0.80 | TYK2 (0.39) | PDE9APDE1CTYK2KCNH2 | |
| SCHEMBL13865780 | 0.79 | TYK2 (0.46) | PDE9APDE1CTYK2 | |
| SCHEMBL4508466 | 0.76 | NPC1 (0.53) | PDE9APDE1CTYK2 | |
| Hydrochloric Acid SCHEMBL4523679 | 0.76 | TYK2 (0.46) | PDE9APDE1CTYK2 | |
| SCHEMBL13865757 | 0.75 | TYK2 (0.42) | PDE9APDE1CTYK2TNKSTNKS2 | |
| SCHEMBL13865769 | 0.75 | TYK2 (0.42) | PDE9APDE1CTYK2KCNH2 | |
| SCHEMBL4512827 | 0.75 | PDE10A (0.46) | PDE9APDE1CTYK2 | |
| SCHEMBL4505595 | 0.74 | CYP1A2 (0.47) | PDE9APDE1CTYK2PARP1 | |
| SCHEMBL13865739 | 0.74 | TYK2 (0.41) | PDE9APDE1CTYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | GALAPAGOS NV (BE) | 2009-05-28 | — | — | US | disclosed |
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | GALAPAGOS NV (BE) | 2009-05-28 | — | — | US | disclosed |
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | GALAPAGOS NV (BE) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | PDE4A, PDE7B, PDE4B | PDE9A 13/4885PDE1C 190/4885TYK2 3816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.